Delivery Order SPE2DB22D2006-SPE2DB25FW3HC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,059.18 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed price delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, PA....
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order valued at $22,621.69 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xeljanz 5 mg tablets in quantities of 60 units, with a ceiling value of $6,416.32. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 5, 2025, and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order does not include a set-aside designation and represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $25,569.98 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets in quantities of 60 units. This firm fixed price delivery order, issued on July 30, 2025, is set to be completed by July 31, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $48,025.04 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- This delivery order, valued at $3,841.62, was awarded on July 30, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. The contract represents a non-competitive set-aside delivery order with firm fixed pricing and a completion deadline of July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance and serves as the prime contractor on this order....
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $21,706.22, is for the delivery of Xeljanz XR 11 mg tablets. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 17, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00,...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3HCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,913.51 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets (60-count units) with an ultimate completion date of August 12, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 through December 2026. The prime vendor contract enables AmerisourceBergen to supply an extensive portfolio of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices—to support military healthcare programs globally. This delivery order for Xeljanz, a branded pharmaceutical treatment, exemplifies the routine fulfillment of critical medical commodities under this strategic vehicle serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 8/11/25 |